Focus Taiwan (06.03.2013)
On June 3, the US pharmaceutical company Janssen-Cilag announced that it would collaborate with National Taiwan University to find a cure for hepatitis B within the next decade. Janssen-Cilag plans to invest $6.6 million throughout the next three years in a joint study with the university. Researchers hope to have new drug candidates within three years and complete clinical trials for a new hepatitis B drug within eight years. According to Chen Pei-jer, professor with National Taiwan University Hospital’s Graduate Institute of Clinical Medicine and research project lead, current hepatitis B drugs were limited by the fact that they could keep the virus in check but could not cure the illness.